How will the COC Protocol help treat breast cancer?
The COC protocol is a patented pharmaceutical composition of four repositioned medications. The medications have long histories treating type-2 diabetes, reducing cholesterol, parasite infection, bacterial infection and inflammation. After four years of clinical research, we know that these drugs – in combination – offer significant therapeutic value for cancer patients. Each of these drugs plays a role in weakening cancer cells and making them more susceptible to standard-of-care therapy (e.g., chemotherapy, immunotherapy).
One of the biggest problems breast cancer patients face is when their cancer becomes resistant to standard-of-care therapies. Multi-drug resistance (MDR) occurs when a patient develops resistance to one or more treatment drugs.
Care Oncology Featured in;
Multi-drug resistance in breast cancer patients is a dangerous phenomenon. When a patient becomes resistant to a cancer drug, the cancer continues growing unchecked until a change in treatment is made — but if your body is resistant to one drug, it has a higher risk of becoming resistant to other drugs.
Breast cancer patients with signs of MDR were included in a published study in the medical journal PLOS One. The study, the result of research led by the College of Medicine at the University of Saskatchewan in Canada, found that a common drug used to treat diabetes is effective in reducing multi-drug resistance once it has occurred.
Want a Case Manager to contact you? It will help your Case Manager better understand your specific circumstances if you fill out your Patient Profile. It will just take a few minutes and will help us assist you better.
A specific class of cholesterol reducing drugs (statins), have shown to reduce the chance of death from breast cancer by up to 38%. Statins do this by reducing the expression of key oncogenes and facilitating a critically important process known as “programmed cell death”, or apoptosis. With the diabetic drug metformin, studies show inhibited growth of multiple types of cancer cells including breast cancer cell lines. Patients under treatment for type 2 diabetes with metformin see increased survivability and reduction in the emergence of new tumors.
Several studies have shown that the development of drug resistance (MDR) was delayed or prevented in cells that were pretreated with metformin. Additional experiments conducted in cells cultures and mouse models of aggressive breast cancer uncovered that MDR was reversed after its onset by metformin use.
Independent clinical studies with various cancers show the drugs used in the COC Protocol produce results by enhancing the therapeutic value of standard-of-care and inhibiting molecular processes that produce multi-drug resistance. Studies also show that patients who are administered one or more of these drugs have greater survivability than patients treated with standard-of-care alone.
Is this treatment still effective when a patient is not receiving chemo or other conventional therapies?
Yes, the available evidence supports that being the case i.e. all the medicines have demonstrated beneficial mechanisms of action in cancer which are not dependent on the co-administration of standard therapies.
That said, there is good data on the ability of these medicines to complement standard treatments, for example, rendering cancer cells more sensitive to chemo or radiotherapy. Therefore, your CO physician may recommend running our metabolic treatment in conjunction with conventional therapy where possible.
However, as metabolic treatment is intended to run long-term, many patients take the protocol as a maintenance regime after standard treatment has been completed or during breaks from standard treatment and as part of a long-term strategy to mitigate the risk of recurrence or metastatic spread.
Fill out the following form to get the COC Protocol and Trial Information:
Breast Cancer and the COC Protocol Drugs
Triple Negative Breast Cancer and the COC Protocol
Discusses the molecular and clinical characteristics of TNBC and goes on to consider therapeutic options. It looks at PARP and mTOR inhibition (relevant for Metformin), angiogenesis inhibition, the role of tubulin (relevant for Mebendazole) and closes with a section on lipophilic statins in terms of anti-proliferative, pro-apoptotic, anti-invasive, and radio- and chemo-sensitizing properties.